AxoGen: Leading company focused on development and commercialization of technologies for peripheral nerve regeneration and repair. Lead product Avance Nerve Graft is a biologically-active OTS human allograft for bridging nerve gaps of up to 70 mm. Target markets represent $2.7B TAM including Trauma $1.9B (>700,000 US procedures). FY 2022 revenue guidance of $137.5M-$140M (from prior $135M-$142M) represents 11.5%-13.5% YOY growth excluding $4.1M in discontinued Avive revenues in 2021. Following announcement of positive RECON top-line results, expect Avance BLA submission in 2H 2023.